Covaxin Triggers Long-Term Immune Response
New Delhi: Home-grown COVID-19 vaccine Covaxin has shown to develop long-term antibody and T-cell memory responses 3 months after the shot in Phase-1 trials.
Bharat Biotech said the safety outcome in Phase-2 trial was found to be tolerable and it is expected that the antibodies produced will last for 6 to 12 months.
Memory T cells are antigen-specific T cells that stay in the body for a long term after an infection is eliminated. No serious adverse reaction was observed, the company said in a research paper.
Covaxin, now in Phase-3 trials, was tried on 380 healthy children and adults during the Phase-2 trials. As many as 13,000 volunteers have been recruited for Phase III trials and a total of 26,000 participants across multiple sites will be needed for the trials. AIIMS Delhi is recruiting more volunteers to join the trials.